Supernus Pharmaceuticals's market cap is currently $1.91B. The company's EPS TTM is $1.068; its P/E ratio is 32.38; Supernus Pharmaceuticals is scheduled to report earnings on March 4, 2025, and the estimated EPS forecast is $0.52. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Income Statement
Total Revenue	$ 607.52M	$ 667.24M	$ 579.77M	$ 520.40M	$ 392.75M
Gross Profit	$ 523.74M	$ 580.02M	$ 504.71M	$ 467.94M	$ 376.10M
Operating Income	$ -5.27M	$ 67.30M	$ 86.03M	$ 173.70M	$ 148.57M
EBITDA	$ 90.04M	$ 153.44M	$ 129.19M	$ 212.40M	$ 180.42M
Net Income	$ 1.32M	$ 60.71M	$ 53.42M	$ 126.95M	$ 113.06M
Balance Sheet
Cash & Short-Term Investments	$ 254.87M	$ 461.33M	$ 339.68M	$ 422.53M	$ 347.07M
Total Assets	$ 1.28B	$ 1.70B	$ 1.69B	$ 1.50B	$ 1.16B
Total Debt	$ 41.53M	$ 437.97M	$ 420.55M	$ 390.33M	$ 375.61M
Net Debt	$ -33.53M	$ 344.85M	$ 217.12M	$ 101.69M	$ 194.23M
Total Liabilities	$ 356.16M	$ 816.30M	$ 873.30M	$ 759.24M	$ 564.85M
Stockholders' Equity	$ 921.52M	$ 886.20M	$ 815.85M	$ 744.86M	$ 595.43M
Cash Flow
Free Cash Flow	$ 110.53M	$ 116.41M	$ 125.08M	$ 134.95M	$ 140.39M
Operating Cash Flow	$ 111.08M	$ 116.83M	$ 127.13M	$ 138.40M	$ 143.13M
Investing Cash Flow	$ 268.73M	$ -216.66M	$ -81.91M	$ -34.70M	$ -157.92M
Financing Cash Flow	$ -397.88M	$ -10.48M	$ -130.42M	$ 3.56M	$ 3.93M

Currency in USD

Supernus Pharmaceuticals Earnings and Revenue History

Income Statement >

Supernus Pharmaceuticals Debt to Assets

Balance Sheet >

Supernus Pharmaceuticals Cash Flow

Cash Flow >

Supernus Pharmaceuticals Forecast EPS vs Actual EPS

Earnings >

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing